Advice and Support. See patient letter and/or other supporting information for contact details of clinician(s) initiating and stabilising patient prior to request for shared care SUPPORTING INFORMATION: Licensed indications: Rufinamide is indicated as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older. NICE CG 137 recommends rufinamide to be considered by the tertiary epilepsy centre for tonic-clonic seizures or Lennox-Gastaut syndrome (if lamotrigine is not effective), if adjunctive treatment is not tolerated or effective.
Advice and Support. How much input is expected from the supervisors in the preparation of the Research Proposal ? What are the expectations of feedback on research, writing etc. How much, how often, in what form? Support with theoretical background, resources, contacts etc. How much can be expected, given the advisory team's knowledge of the research area? Are there relevant personal circumstances (currently known) that might make the supervision or completion of the thesis difficult. Can these be identified and discussed at the outset?
Advice and Support. Sessional Counsellors will receive an orientation to CCL systems7 at the start of the role. Sessional Counsellors may consult the Chief Officer or the CCL Admin team at any time to seek advice and support about CCL Policies and Procedures. Page6 6 CRM stands for Client Record Management. The CRM is a secure Cloud-based database and diary system. 7 Such as the CRM database/appointment diary and forms for recording the outcome of sessions
Advice and Support. See patient letter and/or other supporting information for contact details of clinician(s) initiating and stabilising patient prior to request for shared care. SUPPORTING INFORMATION (see SPCs for complete details/specific guidance available on line at xxxx://xxx.xxxxxxxxx.xxx.xx/) Licensed indications: Glycopyrronium is available as a licensed product, Sialanar®, for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. It should be prescribed by physicians experienced in the treatment of paediatric patients with neurological disorders.
Advice and Support. Any advice or support provided by any SIE Company or Affiliate to Publisher to assist with the development of PlayStation Compatible Products is provided at the complete discretion of the relevant SIE Company or Affiliate, which may change, suspend, remove or disable access to any such advice or support, or impose limits on its use, at any time without incurring liability. Any such advice or support is provided to Publisher on an “AS IS” and “AS AVAILABLE” basis and SIE shall have no liability to Publisher in respect of such support or advice. Any Publisher Property, or other software, materials or information provided by Publisher to any SIE Company or Affiliate in connection with obtaining advice and support is provided at Publisher’s own risk (but without prejudice to SIE’s obligations under Section 20.6). Sony Computer Entertainment
Advice and Support. Any advice or support provided by any SCE Company or Affiliate to Publisher to assist with the development of PlayStation Compatible Products is provided at the complete discretion of the relevant SCE Company or Affiliate, which may change, suspend, remove or disable access to any such advice or support, or impose limits on its use, at any time without incurring liability. Any such advice or support is provided to Publisher on an “AS IS” and “AS AVAILABLE” basis and SCE shall have no liability whatsoever to Publisher in respect of such support or advice. Any Publisher Property, or other software, materials or information provided by Publisher to any SCE Company or Affiliate in connection with obtaining advice and support is provided at Publisher’s own risk (but without prejudice to SCE’s obligations under Section 20.6).
Advice and Support. Esti-mate Software Ltd will provide the Customer with such technical advice and support by telephone, modem, or mail as shall be necessary to resolve Customer’s difficulties and queries in using the Current Release and as more particularly described in the Schedule. All new Release Software will be made available immediately on the Company Web site xxx.xxxxxxxx.xx.xx for download by the Customer. Alternatively, new Release Software will be sent on request by CD but will incur postage and package charges
Advice and Support. Secondary care contact details Telephone No. Bleep Fax Email Specialist Xx Xxxxx 0208 539 5522 Xx Xxxxx 0208 539 5522 Dr Xxx 0208 539 5522 Xx Xxxxxxx 0208 539 5522 Hospital Pharmacy 0208 539 5522 Medicines Information 0208 535 6920 SUPPORTING INFORMATION Licensed indication Dronedarone (Multaq®)) is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dosage and administration Treatment with dronedarone can be initiated in an outpatient setting. The recommended dose is 400 mg twice daily in adults. It should be taken as • one tablet with the morning meal and • one tablet with the evening meal. Grapefruit juice should be avoided when taking dronedarone. If a dose is missed, patients should take the next dose at the regular scheduled time and should not double the dose. Treatment with Class I or III antiarrhythmics (such as flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol, amiodarone) must be stopped before starting dronedarone. Paediatric population - There is no experience in children and adolescents below 18 years of age. Therefore, dronedarone is not recommended in this population. Elderly - Efficacy and safety were comparable in both elderly and younger patients. Although plasma exposure in elderly females was increased in a pharmacokinetic study conducted in healthy subjects, dose adjustments are not considered necessary. Hepatic impairment - Dronedarone is contraindicated in patients with severe hepatic impairment because of the absence of data. No dose adjustment is required in patients with mild or moderate hepatic impairment. Renal impairment - Dronedarone is contraindicated in patients with severe renal impairment (creatinine clearance [CrCl] <30 ml/min). No dose adjustment is required in other patients with renal impairment. Contraindications Hypersensitivity to the active substance or to any of the excipients. Second- or third-degree Atrio-Ventricular block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker). Bradycardia <50 beats per minute (bpm). Patients with stable NYHA Class III heart failure or LVEF <35%. Because of the unexplained results of the ANDROMEDA study, the use of dronedarone in unstable patients with NYHA class III and IV heart failure is contraindicated. Because of limited experience in stable patients with recent (1 to 3 months) NYHA class III heart failu...
Advice and Support. Greening Australia will provide the necessary advice and support to ensure the success of your project. Site Revegetation Plan: Greening Australia will develop a Site Revegetation Action Plan in negotiation with the landholder / manager Ownership: Land managers are to notify Greening Australia if the land to which this agreement applies is likely to be sold or subdivided. The signatory of this agreement is the “landholder” or “land manager” which includes the registered proprietor, property manager or lessee of land leased. Site Availability & Promotion: The land manager will make project sites available for educational, research or promotional purposes, given reasonable notice. The land manager will allow signage and other promotional material on the property where appropriate and as negotiated. Photos and anonymous satellite imagery may be used for promotional purposes. Legislative Requirements: Land managers retain responsibility for complying with all site related legislative requirements including local, State and Commonwealth Acts, policies, permits and licences.
Advice and Support. See patient letter and/or other supporting information for contact details of clinician(s) initiating and stabilising patient prior to request for shared care Group Creatinine clearance (ml/min) Posology and frequency Normal >80 Usual daily dose, 2-4 sub doses Mild 50-79 2/3 usual daily dose, 2 or 3 sub doses Moderate 30-49 1/3 usual daily dose, 2 sub doses Severe <30 1/6 usual daily dose, 1 single intake End-stage renal disease Contra-indicated SUPPORTING INFORMATION:
